BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34587518)

  • 1. Integrated Analysis of Transcriptome and Differential Methylation of Neurofibromatosis Type 2 Vestibular Schwannomas.
    Shi J; Lu D; Gu R; Xie J; Yu L; Sun X; Zhang Y
    World Neurosurg; 2022 Jan; 157():e66-e76. PubMed ID: 34587518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.
    Yuan J; Fu Y; Liu Y
    Medicine (Baltimore); 2023 Dec; 102(50):e36696. PubMed ID: 38115252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schwannomas exhibit distinct size-dependent gene-expression patterns.
    Mehrian-Shai R; Freedman S; Shams S; Doherty J; Slattery W; Hsu NY; Reichardt JK; Andalibi A; Toren A
    Future Oncol; 2015; 11(12):1751-8. PubMed ID: 26075443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of candidate aberrantly methylated and differentially expressed genes in Esophageal squamous cell carcinoma.
    Han BA; Yang XP; Hosseini DK; Zhang P; Zhang Y; Yu JT; Chen S; Zhang F; Zhou T; Sun HY
    Sci Rep; 2020 Jun; 10(1):9735. PubMed ID: 32546690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA microarray analysis of vestibular schwannomas.
    Welling DB; Lasak JM; Akhmametyeva E; Ghaheri B; Chang LS
    Otol Neurotol; 2002 Sep; 23(5):736-48. PubMed ID: 12218628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
    Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
    J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene discovery using a human vestibular schwannoma cDNA library constructed from a patient with neurofibromatosis type 2 (NF2).
    Halum SL; Erbe CB; Friedland DR; Wackym PA
    Otolaryngol Head Neck Surg; 2003 Mar; 128(3):364-71. PubMed ID: 12646839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
    Cumpston EC; Rhodes SD; Yates CW
    Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
    Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
    Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular biology and novel treatments of vestibular schwannomas.
    Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
    J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genesis and biology of vestibular schwannomas.
    Roche PH; Bouvier C; Chinot O; Figarella-Branger D
    Prog Neurol Surg; 2008; 21():24-31. PubMed ID: 18810196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on Tumor Biology in Vestibular Schwannoma.
    Nourbakhsh A; Dinh CT
    Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology of vestibular schwannomas.
    Chang LS; Welling DB
    Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.
    Dewan R; Pemov A; Kim HJ; Morgan KL; Vasquez RA; Chittiboina P; Wang X; Chandrasekharappa SC; Ray-Chaudhury A; Butman JA; Stewart DR; Asthagiri AR
    Neuro Oncol; 2015 Apr; 17(4):566-73. PubMed ID: 25452392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
    Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
    Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of candidate aberrantly methylated and differentially expressed genes in thyroid cancer.
    Tu Y; Fan G; Xi H; Zeng T; Sun H; Cai X; Kong W
    J Cell Biochem; 2018 Nov; 119(11):8797-8806. PubMed ID: 30069928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma.
    Irving RM; Harada T; Moffat DA; Hardy DG; Whittaker JL; Xuereb JH; Maher ER
    Am J Otol; 1997 Nov; 18(6):754-60. PubMed ID: 9391673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas.
    Lee JD; Kwon TJ; Kim UK; Lee WS
    PLoS One; 2012; 7(1):e30418. PubMed ID: 22295085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas.
    Koutsimpelas D; Ruerup G; Mann WJ; Brieger J
    ORL J Otorhinolaryngol Relat Spec; 2012; 74(1):33-7. PubMed ID: 22249120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.